CN104640985B - 特异结合性或功能性蛋白的转座介导鉴定 - Google Patents

特异结合性或功能性蛋白的转座介导鉴定 Download PDF

Info

Publication number
CN104640985B
CN104640985B CN201380048308.7A CN201380048308A CN104640985B CN 104640985 B CN104640985 B CN 104640985B CN 201380048308 A CN201380048308 A CN 201380048308A CN 104640985 B CN104640985 B CN 104640985B
Authority
CN
China
Prior art keywords
cells
seq
sequence
expression
transposase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380048308.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104640985A (zh
Inventor
乌尔夫·格劳乌德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NBE-Therapeutics AG
Original Assignee
NBE-Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NBE-Therapeutics AG filed Critical NBE-Therapeutics AG
Publication of CN104640985A publication Critical patent/CN104640985A/zh
Application granted granted Critical
Publication of CN104640985B publication Critical patent/CN104640985B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201380048308.7A 2012-07-18 2013-07-18 特异结合性或功能性蛋白的转座介导鉴定 Active CN104640985B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261673144P 2012-07-18 2012-07-18
US61/673,144 2012-07-18
EP12178529.9 2012-07-30
EP12178529.9A EP2692865B1 (en) 2012-07-30 2012-07-30 Transposition-mediated identification of specific binding or functional proteins
PCT/EP2013/065214 WO2014013026A1 (en) 2012-07-18 2013-07-18 Transposition-mediated identification of specific binding or functional proteins

Publications (2)

Publication Number Publication Date
CN104640985A CN104640985A (zh) 2015-05-20
CN104640985B true CN104640985B (zh) 2021-05-11

Family

ID=49775745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380048308.7A Active CN104640985B (zh) 2012-07-18 2013-07-18 特异结合性或功能性蛋白的转座介导鉴定

Country Status (18)

Country Link
US (2) US10174309B2 (cg-RX-API-DMAC7.html)
EP (2) EP2692865B1 (cg-RX-API-DMAC7.html)
JP (1) JP6043431B2 (cg-RX-API-DMAC7.html)
CN (1) CN104640985B (cg-RX-API-DMAC7.html)
AU (1) AU2013291971B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015000836B1 (cg-RX-API-DMAC7.html)
CA (1) CA2878982C (cg-RX-API-DMAC7.html)
DK (1) DK2692865T3 (cg-RX-API-DMAC7.html)
ES (1) ES2528892T3 (cg-RX-API-DMAC7.html)
IL (1) IL236771A (cg-RX-API-DMAC7.html)
IN (1) IN2015DN01301A (cg-RX-API-DMAC7.html)
MX (1) MX338911B (cg-RX-API-DMAC7.html)
NZ (1) NZ705074A (cg-RX-API-DMAC7.html)
PT (1) PT2692865E (cg-RX-API-DMAC7.html)
SG (1) SG11201500280XA (cg-RX-API-DMAC7.html)
SI (1) SI2692865T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014013026A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500203B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
CA3001941A1 (en) 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
CN109311982A (zh) 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
MX2018008926A (es) 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
JP2019513415A (ja) 2016-04-04 2019-05-30 イーティーエッチ チューリッヒ タンパク質産生及びライブラリー生成のための哺乳類細胞株
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
BR112019009484A2 (pt) 2016-12-09 2019-07-30 Gliknik Inc otimização de fabricação de gl-2045, um stradomer multimerizador
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
WO2019219947A1 (en) * 2018-05-18 2019-11-21 Sorbonne Universite Molecular tools and methods for transgene integration and their transposition dependent expression
WO2019246486A2 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
KR102559149B1 (ko) * 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
JP2020146014A (ja) * 2019-03-15 2020-09-17 株式会社東芝 トランスポゼース活性測定用ベクター、トランスポゼース活性測定用キット、トランスポゼース活性測定方法及び細胞分離方法
AU2020320910A1 (en) * 2019-07-30 2022-03-10 Akeso Biopharma, Inc. Anti-human p40 protein domain antibody and use thereof
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
CN111139264B (zh) * 2020-01-20 2021-07-06 天津达济科技有限公司 一种基于线性双链dna分子在哺乳动物细胞系内构建单域抗体库的方法
KR102937659B1 (ko) 2020-02-19 2026-03-10 우시 바이올로직스 아일랜드 리미티드 강화된 발현 시스템 및 그 사용방법
MX2022012005A (es) * 2020-03-27 2022-10-21 Ddbio Co Ltd Shang Hai Metodo para el despliegue de anticuerpo biespecifico en la superficie de celula de mamifero y vector.
CN111471714A (zh) * 2020-05-07 2020-07-31 西南大学 Minos转座子系统介导的真核生物转基因细胞系及构建方法
CA3203531A1 (en) 2020-12-30 2022-07-07 Simon Olivares Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
US20240360436A1 (en) * 2021-03-31 2024-10-31 DDBio. Co., Ltd. Vector and method for screening functional antigen-binding protein
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025158420A1 (en) 2024-01-25 2025-07-31 Nanocell Therapeutics Holdings B.V. Methods and composition for inducing activation and dna expression in t-cells
WO2025169168A1 (en) 2024-02-09 2025-08-14 Nanocell Therapeutics Holdings B.V. Extracorporeal transfection of immune effector cells
WO2025216732A1 (en) * 2024-04-10 2025-10-16 Duke University Methods and compositions relating to ecdna biogenesis
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
WO2026159700A1 (en) 2025-01-27 2026-07-30 Nanocell Therapeutics Holdings B.V. Methods and composition for inducing activation and dna expression in t-cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081628A1 (ja) * 2010-12-15 2012-06-21 大学共同利用機関法人情報・システム研究機構 タンパク質の生産方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6218185B1 (en) 1996-04-19 2001-04-17 The United States Of America As Represented By The Secretary Of Agriculture Piggybac transposon-based genetic transformation system for insects
DK0973928T3 (da) 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US7105343B1 (en) 2000-10-31 2006-09-12 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector Piggybac
US6962810B2 (en) 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
KR20040024560A (ko) 2001-06-14 2004-03-20 바스프 코포레이션 광안정화 잔기를 포함하는 광안정화 중합체, 그로부터제조된 물품 및 그의 제조방법
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
WO2003106639A2 (en) * 2002-06-14 2003-12-24 Dyax Corporation Recombination of nucleic acid library members
CA2492074A1 (en) 2002-07-10 2004-01-15 Stratagene Humanized renilla reniformis green fluorescent protein as a scaffold
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7932088B1 (en) 2005-04-25 2011-04-26 University Of Notre Dame Du Lac High efficiency transformation of Plasmodium falciparum by the lepidopteran transposon, piggyBac
US20060252140A1 (en) 2005-04-29 2006-11-09 Yant Stephen R Development of a transposon system for site-specific DNA integration in mammalian cells
KR101323563B1 (ko) * 2005-10-18 2013-10-29 니토 보세키 가부시기가이샤 항체를 생산하는 트랜스제닉 누에와 그의 제조방법
US20090042297A1 (en) * 2007-06-01 2009-02-12 George Jr Alfred L Piggybac transposon-based vectors and methods of nucleic acid integration
US9228180B2 (en) 2007-07-04 2016-01-05 Max-Delbruck-Centrum Fur Molekulare Medizin Polypeptide variants of sleeping beauty transposase
CA2698727A1 (en) 2007-09-17 2009-03-26 Affomix Corporation Increasing specificity in a scfv screen using dual bait reporters
US7863425B2 (en) * 2007-09-26 2011-01-04 Cornell University Compositions and methods for inhibiting Yersinia pestis infection
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
EP2235181A1 (en) 2008-01-11 2010-10-06 MorphoSys AG Display vectors and methods and uses thereof
US9131671B2 (en) * 2008-02-01 2015-09-15 Entogenetics, Inc. Methods, compositions and systems for production of recombinant spider silk polypeptides
JP2009225781A (ja) * 2008-02-29 2009-10-08 Neosilk Co Ltd カイコを用いた糖鎖構造に特徴を有する糖蛋白質の製造方法
EP2098536A1 (en) * 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
US20100311116A1 (en) * 2009-06-04 2010-12-09 Excellgene Sa Fast generation of high expression stable cell lines expressing recombinant proteins under minimal and short-term selective pressure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081628A1 (ja) * 2010-12-15 2012-06-21 大学共同利用機関法人情報・システム研究機構 タンパク質の生産方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Selection of functional human antibodies from retroviral display libraries;Johannes et al;《Nucleic Acids Research》;20051231;摘要,第2页第二段-第3页第2段,图1-4 *

Also Published As

Publication number Publication date
EP2692865A1 (en) 2014-02-05
PT2692865E (pt) 2015-02-06
ES2528892T3 (es) 2015-02-13
US20190153433A1 (en) 2019-05-23
AU2013291971B2 (en) 2016-02-04
JP2015522286A (ja) 2015-08-06
MX338911B (es) 2016-05-05
SI2692865T1 (sl) 2015-03-31
NZ705074A (en) 2017-04-28
BR112015000836B1 (pt) 2021-12-21
EP2692865B1 (en) 2014-12-10
EP2687599A1 (en) 2014-01-22
US10174309B2 (en) 2019-01-08
CA2878982A1 (en) 2014-01-23
HK1209779A1 (en) 2016-04-08
IL236771A (en) 2016-09-29
US20150152406A1 (en) 2015-06-04
CA2878982C (en) 2017-01-03
DK2692865T3 (en) 2015-02-16
SG11201500280XA (en) 2015-02-27
WO2014013026A1 (en) 2014-01-23
AU2013291971A1 (en) 2015-02-05
CN104640985A (zh) 2015-05-20
WO2014013026A8 (en) 2014-12-04
JP6043431B2 (ja) 2016-12-14
IN2015DN01301A (cg-RX-API-DMAC7.html) 2015-07-03
ZA201500203B (en) 2015-12-23
MX2015000885A (es) 2015-07-14
BR112015000836A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
CA2878982C (en) Transposition-mediated identification of specific binding or functional proteins
JP6019540B2 (ja) 抗原特異的又はリガンド特異的結合タンパク質の同定
HK1209779B (en) Transposition-mediated identification of specific binding or functional proteins
AU2014274595B2 (en) Identification of antigen- or ligand-specific binding proteins
HK1149280B (en) Identification of antigen- or ligand-specific binding proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1209779

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant